 |
 |
|
 |
 |
Comments on Paper and Primary News |
 |
  |
| |
Primary News: Neurotoxic Homocysteine Metabolite Boosts Intracellular Aβ
Comment by: Barney Dwyer, Hyoung-gon Lee, Akihiko Nunomura, George Perry, ARF Advisor (Disclosure), Mark A. Smith (Disclosure), Xiongwei Zhu
|
 |
 |
Submitted 31 May 2005
| Permalink
|
Posted 31 May 2005
|
 |
 |
Homocysteine and AD: More Than Meets the Eye
Hyoung-gon Lee, Mark A. Smith, Barney Dwyer, Aki Nunomura, George Perry, Xiongwei Zhu
Increased levels of plasma homocysteine (HC), a key metabolic intermediate in sulfur amino acid metabolism, have been associated with several disorders including Alzheimer disease (AD). While HC is toxic in cell culture models including primary cortical neurons, the mechanism of HC toxicity and the role of HC in disease pathogenesis remain unclear. Hasegawa and colleagues hypothesized that homocysteic acid (HA), an oxidant product of HC, might play an important role in the pathogenesis of AD by regulating amyloid-β (Aβ) production. They demonstrate that HA dramatically decreases the extracellular level of Aβ42 but increases the intracellular level of Aβ42 in primary cortical neurons and APP-overexpressing CHO cells, and they suggest that this is associated with HA toxicity. This finding led them to show that a γ-secretase inhibitor prevents HA toxicity. While the level of HC is increased both in plasma and CSF in AD, there is no change in...
Read more
Homocysteine and AD: More Than Meets the Eye
Hyoung-gon Lee, Mark A. Smith, Barney Dwyer, Aki Nunomura, George Perry, Xiongwei Zhu
Increased levels of plasma homocysteine (HC), a key metabolic intermediate in sulfur amino acid metabolism, have been associated with several disorders including Alzheimer disease (AD). While HC is toxic in cell culture models including primary cortical neurons, the mechanism of HC toxicity and the role of HC in disease pathogenesis remain unclear. Hasegawa and colleagues hypothesized that homocysteic acid (HA), an oxidant product of HC, might play an important role in the pathogenesis of AD by regulating amyloid-β (Aβ) production. They demonstrate that HA dramatically decreases the extracellular level of Aβ42 but increases the intracellular level of Aβ42 in primary cortical neurons and APP-overexpressing CHO cells, and they suggest that this is associated with HA toxicity. This finding led them to show that a γ-secretase inhibitor prevents HA toxicity. While the level of HC is increased both in plasma and CSF in AD, there is no change in HA levels. However, interestingly, increasing HC can effectively enhance HA toxicity manyfold, presumably also via the regulation of Aβ.
These interesting findings shed some new light on how increased levels of HC may contribute to the pathogenesis of AD—increased HC enhances HA toxicity, which results in intraneuronal accumulation of Aβ42 and subsequent neuronal death. However, such a conclusion warrants tempering. Indeed, it is ambiguous in this study whether intracellular Aβ42 actually leads to neuronal death, since there was a threefold increase of intracellular Aβ42 in ten μM HA-treated cells, yet no apparent neuronal death at this concentration. Nevertheless, it raises the question of how HA regulates Aβ42. As suggested by the authors, Aβ upregulation might involve oxidative stress, and this is consistent with in vivo and in vitro studies showing that oxidative stress precedes Aβ accumulation (Nunomura et al., 2001; Lee et al., 2004). Thus, it will be of interest to directly determine whether HA affects Aβ accumulation by oxidative stress and also the sequence of events regarding the elevation of HC and Aβ accumulation in AD patients. Recently we proposed that elevated HC may participate in a vicious cycle involving iron dysregulation, resulting in oxidative stress and other early events seen in AD (Dwyer et al., 2004). The increased vulnerability against HA by the elevated level of HC may also contribute to such a vicious cycle and enhance oxidative damage. This article provides a solid foundation for such studies.
References:
Dwyer BE, Raina AK, Perry G, Smith MA. Homocysteine and Alzheimer's disease: a modifiable risk? Free Radic Biol Med. 2004 Jun 1;36(11):1471-5. Abstract
Lee HG, Casadesus G, Zhu X, Takeda A, Perry G, Smith MA. Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann N Y Acad Sci. 2004 Jun;1019:1-4. Review. Abstract
Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001 Aug;60(8):759-67. Abstract
View all comments by Barney Dwyer
View all comments by Hyoung-gon Lee
View all comments by Akihiko Nunomura
View all comments by George Perry
View all comments by Mark A. Smith
View all comments by Xiongwei Zhu
|
 |

|
| |
Primary News: Neurotoxic Homocysteine Metabolite Boosts Intracellular Aβ
Comment by: Andrew McCaddon (Disclosure)
|
 |
 |
Submitted 31 May 2005
| Permalink
|
Posted 6 June 2005
|
 |
 |
Homocysteine, oxidative stress, and AD: An even more vicious cycle!
Commenting on Hasegawa et al., Dwyer and collaborators note that elevated homocysteine may participate in a vicious cycle involving iron dysregulation, resulting in oxidative stress seen in AD (Dwyer et al., 2004). Their proposed mechanism suggests that localized heme deficiency in AD brain could result in loss of cystathionine β-synthase redox responsiveness and incur increased homocysteine during periods of oxidative stress.
It is also important to note that the other major route of homocysteine metabolism, the methionine synthase reaction, is also exquisitely sensitive to oxidative stress. We have proposed a complementary mechanism whereby such stress impairs methionine synthase activity (McCaddon et al 2002; McCaddon and Kelly, 1992, and see Alzheimer Research Forum "A cobalaminergic hypothesis.")
Taken together, these two mechanisms suggest that it might be important to address oxidative stress as well as B vitamin deficiency in cognitively impaired patients presenting with...
Read more
Homocysteine, oxidative stress, and AD: An even more vicious cycle!
Commenting on Hasegawa et al., Dwyer and collaborators note that elevated homocysteine may participate in a vicious cycle involving iron dysregulation, resulting in oxidative stress seen in AD (Dwyer et al., 2004). Their proposed mechanism suggests that localized heme deficiency in AD brain could result in loss of cystathionine β-synthase redox responsiveness and incur increased homocysteine during periods of oxidative stress.
It is also important to note that the other major route of homocysteine metabolism, the methionine synthase reaction, is also exquisitely sensitive to oxidative stress. We have proposed a complementary mechanism whereby such stress impairs methionine synthase activity (McCaddon et al 2002; McCaddon and Kelly, 1992, and see Alzheimer Research Forum "A cobalaminergic hypothesis.")
Taken together, these two mechanisms suggest that it might be important to address oxidative stress as well as B vitamin deficiency in cognitively impaired patients presenting with hyperhomocysteinaemia. We have observed promising clinical effects using such an approach in several recent cases [McCaddon A, Davies G. Int.J.Ger.Psych. 2005 (in press)]. A randomized controlled clinical trial is now underway to formally evaluate this novel synergistic approach in these patients.
References:
Dwyer BE, Raina AK, Perry G, Smith MA. Homocysteine and Alzheimer's disease: a modifiable risk? Free Radic Biol Med. 2004 Jun 1;36(11):1471-5.
Abstract
McCaddon A, Regland B, Hudson P, Davies G. Functional vitamin B(12) deficiency and Alzheimer disease.
Neurology. 2002 May 14;58(9):1395-9. Abstract
McCaddon A, Kelly CL. Alzheimer's disease: A "cobalaminergic" hypothesis. Med Hypotheses. 1992 Mar;37(3):161-5. Review. Abstract Reproduced on ARF at:
The "Cobalaminergic" hypothesis)
McCaddon A. Davies G. Co-administration of N-acetylcysteine, vitamin B12 and folate in cognitively impaired hyperhomocysteinaemic patients Int J Ger Psych. 2005 (in press).
View all comments by Andrew McCaddon
|
 |

|
| |
Primary News: Neurotoxic Homocysteine Metabolite Boosts Intracellular Aβ
Comment by: Sigfrido Scarpa
|
 |
 |
Submitted 7 June 2005
| Permalink
|
Posted 7 June 2005
|
 |
 |
I look at the results reported bearing in mind that homocysteine is one of the products of S-adenosylmethionine metabolism. It has been recently reported by my group ( Scarpa et al., 2003 and Fuso et al., 2005) that both PS1 and BACE are regulated by DNA methylation and that accumulation of homocysteine, obtained by starvation of B12 and folate in the culture medium, increased amyloid production. As far as amyloid release (Fig. 1) and the ratio between intracellular and extracellular concentrations of the two Aβ species, my comment is that HA administration, by changing the methylation status of membrane lipids, among several other events, could decrease the fluidity of the membranes and therefore the secretion. Consequently, amyloid accumulates inside the cells (Fig. 3A and 4).
I think it is important to look carefully at the main metabolism in which homocysteine is involved. The main product in the pathway is S-adenosylmethionine, the donor of all the methylation reactions. The...
Read more
I look at the results reported bearing in mind that homocysteine is one of the products of S-adenosylmethionine metabolism. It has been recently reported by my group ( Scarpa et al., 2003 and Fuso et al., 2005) that both PS1 and BACE are regulated by DNA methylation and that accumulation of homocysteine, obtained by starvation of B12 and folate in the culture medium, increased amyloid production. As far as amyloid release (Fig. 1) and the ratio between intracellular and extracellular concentrations of the two Aβ species, my comment is that HA administration, by changing the methylation status of membrane lipids, among several other events, could decrease the fluidity of the membranes and therefore the secretion. Consequently, amyloid accumulates inside the cells (Fig. 3A and 4).
I think it is important to look carefully at the main metabolism in which homocysteine is involved. The main product in the pathway is S-adenosylmethionine, the donor of all the methylation reactions. The accumulation of homocysteine, either pathologic or administered (please note that Frauscher, in the paper cited by the authors, used the thiolactone that produces both HC and HA), reverses the reaction controlled by S-adenosylhomocysteine-hydrolase, blocking the methylation reaction cycle and therefore inducing a generalized hypomethylation.
View all comments by Sigfrido Scarpa
|
 |

|
| |
Primary News: Neurotoxic Homocysteine Metabolite Boosts Intracellular Aβ
Comment by: Mary Reid
|
 |
 |
Submitted 6 June 2005
| Permalink
|
Posted 10 June 2005
|
 |
 |
Zou et al. (1) report that γ-secretase is involved in the processing of megalin. In view of the fact that megalin binds cubilin, the receptor for B12-intrinsic factor complex, and mediates uptake of the vitamin B12-transcobalamin complex (2), what are the implications for AD?
References:
1. Zou Z, Chung B, Nguyen T, Mentone S, Thomson B, Biemesderfer D.
Linking receptor-mediated endocytosis and cell signaling: evidence for regulated intramembrane proteolysis of megalin in proximal tubule. J Biol Chem. 2004 Aug 13;279(33):34302-10. Epub 2004 Jun 4. Abstract
2. Gliemann J. Receptors of the low density lipoprotein (LDL) receptor family in man. Multiple functions of the large family members via interaction with complex ligands.
Biol Chem. 1998 Aug-Sep;379(8-9):951-64. Review. Abstract
View all comments by Mary Reid
|
 |

|
| |
Primary News: Neurotoxic Homocysteine Metabolite Boosts Intracellular Aβ
Comment by: Mary Reid
|
 |
 |
Submitted 26 May 2005
| Permalink
|
Posted 18 June 2005
|
 |
 |
Does homocysteic acid also induce expression of HERP ( Homocysteine- and endoplasmic reticulum stress-inducible protein, ubiquitin-like domain-containing, 1)?
Sai et al. (1) report that HERP increases the generation of amyloid beta-protein (Abeta) and that Herp interacts with presenilin (PS). References: FEBS Lett. 2003 Oct 9;553(1-2):151-6.
The ubiquitin-like domain of Herp is involved in Herp degradation, but not necessary for its enhancement of amyloid beta-protein generation.
Sai X, Kokame K, Shiraishi H, Kawamura Y, Miyata T, Yanagisawa K, Komano H.
Department of Dementia Research, National Institute for Longevity Sciences, Obu, Aichi, Japan.
Herp is an endoplasmic reticulum (ER)-stress-inducible membrane protein, which has a ubiquitin-like domain (ULD). However, its biological function is as yet unknown. Previously, we reported that a high expression level of Herp in cells increases the generation of amyloid beta-protein (Abeta) and that Herp interacts with presenilin (PS). Here, we addressed the role of the ULD of Herp in Abeta generation and intracellular Herp stability. We found that the ULD is not essential for the enhancement of Abeta generation by Herp expression and the interaction of Herp with PS, but is involved in the rapid degradation of Herp, most likely via the ubiquitin/proteasome pathway. Thus, the ULD of Herp most likely plays a role in the regulation of the intracellular level of Herp under ER stress.
PMID: 14550564 [PubMed - indexed for MEDLINE] View all comments by Mary Reid
|
 |
 |
| |
Submit a Comment on this Paper |
 |
 |
 |
 |
| |
 |
 |
| |
|
|
|
 |